Balcinrenone
A nonsteroidal antimineralocorticoid drug
Balcinrenone is a nonsteroidal antimineralocorticoid that was developed for the treatment of congestive heart failure and hypertension. It acts as a selective mineralocorticoid receptor antagonist, blocking the effects of aldosterone in the body.
Mechanism of Action[edit | edit source]
Balcinrenone functions by inhibiting the action of aldosterone, a hormone that increases the reabsorption of sodium and water in the kidneys. By blocking aldosterone, balcinrenone promotes the excretion of sodium and water, which helps to lower blood pressure and reduce fluid overload in conditions such as congestive heart failure.
Pharmacokinetics[edit | edit source]
Balcinrenone is administered orally and is absorbed through the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily through the kidneys. The drug has a half-life that allows for once-daily dosing, making it convenient for patients.
Clinical Use[edit | edit source]
Balcinrenone was investigated for its potential use in treating conditions like heart failure and hypertension. However, it did not reach the market, and its development was discontinued. Despite this, the study of balcinrenone has contributed to the understanding of mineralocorticoid receptor antagonists and their role in cardiovascular therapy.
Side Effects[edit | edit source]
As with other mineralocorticoid receptor antagonists, potential side effects of balcinrenone may include hyperkalemia, hypotension, and renal impairment. Patients taking this class of drugs require monitoring of serum potassium levels and renal function.
Related Compounds[edit | edit source]
Balcinrenone is part of a class of drugs known as nonsteroidal antimineralocorticoids. Other drugs in this class include eplerenone and spironolactone, which are used clinically to treat similar conditions.
Research and Development[edit | edit source]
The development of balcinrenone was part of a broader effort to create more selective and effective mineralocorticoid receptor antagonists. Although balcinrenone itself was not marketed, research in this area continues to be important for developing new treatments for cardiovascular diseases.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
